Postoperative cognitive dysfunction
Conditions
Interventions
F:Induction of anesthesia: propofol 1.5-2.0 mg-kg-1, esketamine 0.4 mg-kg-1. Rocuronium bromide 0.6 mg-kg-1. Anesthesia maintenance: esketamine 0.1-0.2 mg-kg-1-h-1 and propofol 4-10 mg-kg-1-h-1 admini
C:Induction of anesthesia: propofol 1.5-2.0 mg-kg-1, sufentanil 0.4 µg-kg-1. Rocuronium bromide 0.6 mg-kg-1 was injected. Anesthesia maintenance: remifentanil 5-10 µg-kg-1-h-1 and propofol 4-10 mg-kg-
Sponsors
Liaoning Cancer Hospital & Institute
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients aged =65 years, of either sex, who were to undergo thoracoscopic lobectomy; American Society of Anesthesiologists (ASA) physical status classification of Class II or Class III; body mass index (BMI) between 18.5 and 30.0 kg/m²; no serious heart and lung diseases affecting surgery and anesthesia; no significant abnormalities in liver or kidney function; preoperative summary mental status examination (MMSE) score =26, There were no serious heart, brain, lung or other important organ diseases affecting surgery and anesthesia, and no obvious abnormality in liver and kidney functions; the score of preoperative MMSE was =26.
Exclusion criteria
Exclusion criteria: Allergy to the anesthetics used in the study; severe cardiac, hepatic, pulmonary, or renal insufficiency; preoperative cognitive dysfunction (MMSE score <26) or psychiatric disorders; long-term opioid treatment; pregnant or lactating females; patients weighing less than 40 kg or more than 100 kg; patients on lithium therapy or with contraindications to the use of the LiDCO system, such as puncture, or other conditions not suitable for participation in the study. Patients with severe peripheral vascular disease or anatomical changes at the puncture site, localized skin and soft tissue infections, severe coagulation disorders, or other conditions that make participation in this study inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative cognitive function; | — |
Countries
China
Contacts
Public ContactHuangZeQing
Liaoning Cancer Hospital & Institute
Outcome results
None listed